Yuichi Ishikawa

Active 1988–2025

161
Papers
40,557
Citations
91
h-index
140
i10-index

Citations

Citations per year for Yuichi Ishikawa1963: 1 citations1964: 1 citations1967: 1 citations1984: 1 citations1986: 1 citations1988: 1 citations1990: 1 citations1991: 3 citations1992: 10 citations1993: 5 citations1994: 6 citations1995: 5 citations1996: 5 citations1997: 18 citations1998: 12 citations1999: 31 citations2000: 30 citations2001: 26 citations2002: 36 citations2003: 30 citations2004: 38 citations2005: 64 citations2006: 53 citations2007: 99 citations2008: 185 citations2009: 247 citations2010: 315 citations2011: 484 citations2012: 553 citations2013: 585 citations2014: 486 citations2015: 462 citations2016: 484 citations2017: 421 citations2018: 473 citations2019: 1,321 citations2020: 1,427 citations2021: 1,238 citations2022: 907 citations2023: 677 citations2024: 1,033 citations2025: 436 citations2026: 28 citations1965–1966: no citations, so these years are not shown1968–1983: no citations, so these years are not shown1985: no citations, so this year is not shown1987: no citations, so this year is not shown1989: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,979 citing papers, 25.4% of this breakdownChina: 2,397 citing papers, 15.3% of this breakdownJapan: 1,352 citing papers, 8.6% of this breakdownUnited Kingdom: 752 citing papers, 4.8% of this breakdownItaly: 732 citing papers, 4.7% of this breakdownGermany: 665 citing papers, 4.3% of this breakdownFrance: 521 citing papers, 3.3% of this breakdownSouth Korea: 422 citing papers, 2.7% of this breakdownCanada: 415 citing papers, 2.7% of this breakdownSpain: 362 citing papers, 2.3% of this breakdownAustralia: 332 citing papers, 2.1% of this breakdownNetherlands: 308 citing papers, 2% of this breakdown
0%25.4%Other 21.8%

Fields

  • Medicine59.5%
  • Biochemistry, Genetics and Molecular Biology28.9%
  • Nursing4.3%
  • Immunology and Microbiology1.9%
  • Computer Science1.6%
  • Chemistry0.7%
  • Other3.1%

Topics

  • Lung Cancer Treatments and Mutations7.6%
  • Lung Cancer Diagnosis and Treatment5.2%
  • Lung Cancer Research Studies4.9%
  • Cancer Genomics and Diagnostics2.7%
  • Radiomics and Machine Learning in Medical Imaging2%
  • Gut microbiota and health1.9%
  • Other75.7%

Coauthors

All papers

Open in search
  1. The 2015 World Health Organization Classification of Lung Tumors

    Authors: , , , , , , , , , , , , , , , , , , - Journal of Thoracic Oncology 2015 cited by 4,546

  2. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

    Authors: , , , , , , , , , , , , , - Nature 2013 cited by 2,219

  3. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Wilbur A. Franklin, Adi F. Gazdar, Michael K. Gould, P S Hasleton, Douglas W. Henderson, Bruce Johnson, David Johnson, Keith M. Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor L. Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming‐Sound Tsao, David Yankelewitz - Journal of Thoracic Oncology 2011 cited by 4,843

  4. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer

    Authors: , , , , , , , , , , , , , , , , , - Nature 2007 cited by 5,456

  5. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis

    Authors: , , , , , , , , , , , , , , , - The Lancet 2007 cited by 2,523

  6. FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development

    Authors: , , - Cancer Science 2019 cited by 295

  7. RET, ROS1 and ALK fusions in lung cancer

    Authors: , , , , , , , , , , , , , , , - Nature Medicine 2012 cited by 1,330

  8. ATP Citrate Lyase: Activation and Therapeutic Implications in Non–Small Cell Lung Cancer

    Authors: , , , , , , , , , , , , - Cancer Research 2008 cited by 399

  9. The sense of agency in human-AI interactions

    Authors: , , , , , , - Knowledge-Based Systems, Knowl. Based Syst. 2024 cited by 43

  10. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes

    Authors: , , , , , , , , , , - Oncotarget 2017 cited by 119

  11. A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2017 cited by 148

  12. EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

    Authors: , , , , , , , , , , , , , , - New England Journal of Medicine 2010 cited by 1,181

  13. Frequent inactivation of A20 in B-cell lymphomas

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2009 cited by 549

  14. JNETS clinical practice guidelines for gastroenteropancreatic neuroendocrine neoplasms: diagnosis, treatment, and follow-up: a synopsis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Noritoshi Kobayashi, Nao Fujimori, Yoshitaka Honma, Chigusa Morizane, Shinya Uchino, Kiyomi Horiuchi, Masanori Yamasaki, Jun Matsubayashi, Yuichi Sato, Masau Sekiguchi, Shinichi Abe, Takuji Okusaka, Mitsuhiro Kida, Wataru Kimura, Masao Tanaka, Yoshiyuki Majima, Robert T. Jensen, Koichi Hirata, Masayuki Imamura, Shinji Üemoto - Journal of Gastroenterology 2021 cited by 160

  15. Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Birgit I. Lissenberg‐Witte, Dirk J. Kuik - Modern Pathology 2012 cited by 241

  16. Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma

    Authors: , , , , , - Cancer Management and Research 2019 cited by 49

  17. Clinical significance of intratumoral HER2 heterogeneity on trastuzumab efficacy using endoscopic biopsy specimens in patients with advanced HER2 positive gastric cancer

    Authors: , , , , , , , , , , , , , , , - Gastric Cancer 2018 cited by 76

  18. A mouse model for EML4-ALK -positive lung cancer

    Authors: , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2008 cited by 511

  19. Molecular alterations of coexisting thyroid papillary carcinoma and anaplastic carcinoma: identification of TERT mutation as an independent risk factor for transformation

    Authors: , , , , , , , , , , , , - Modern Pathology 2017 cited by 105

  20. Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer

    Authors: , , , , , , , , , , , , , , , - Journal of Gastroenterology 2018 cited by 104

  21. Identification of Meflin as a Potential Marker for Mesenchymal Stromal Cells

    Authors: , , , , , , , , , , , , , , , , , , , - Scientific Reports 2016 cited by 103

  22. Prediction of early colorectal cancer metastasis by machine learning using digital slide images

    Authors: , , , , , , , , - Computer Methods and Programs in Biomedicine, Comput. Methods Programs Biomed. 2019 cited by 79

  23. KIF5B-ALK, a Novel Fusion Oncokinase Identified by an Immunohistochemistry-based Diagnostic System for ALK-positive Lung Cancer

    Authors: , , , , , , , , , , , , , - Clinical Cancer Research 2009 cited by 712

  24. Chemically Modified DNA Aptamers Bind Interleukin-6 with High Affinity and Inhibit Signaling by Blocking Its Interaction with Interleukin-6 Receptor

    Authors: , , , , , , , , , , , , , , - Journal of Biological Chemistry 2014 cited by 150